# Revvity, Inc. (RVTY)

> Source: Nexqual · https://nexqual.com/RVTY · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Revvity, Inc. (RVTY), nexqual.com/RVTY" · informational, not investment advice.

**Price:** USD 157.36 (+0.48% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 156.61 · day 154.89–161.52 · 52w 81.22–166.25 · market cap $17.6B · NYQ

## Key facts
- Last four reported quarters (through Jul 5, 2026): revenue $2.91B, net income $238M (8.2% margin), free cash flow $558M (SEC filings).
- Valuation: P/E 73.9x (avg 39.1x at the last 3 fiscal year-ends).
- Earnings quality: non-operating income -$98.1M vs operating income $359M over the last four quarters; P/E excluding non-operating income ≈53.7x (estimate: non-operating income taxed at the company's 9% effective rate).
- Insider open-market sales, last ~7 months: 5 Form 4 filings, $1.3M; 0 not under a Rule 10b5-1 plan ($0K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Hold (mean 2.78 on a 1–5 scale) (18 analysts), mean target USD 147.53 (range 110–175).
- Total return with dividends: 1Y +61.6% vs S&P 500 +14.9%; 5Y -9.8% vs S&P 500 +80.3%.
- Next earnings: 2026-11-03, EPS estimate USD 1.3, revenue estimate $695M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $3.83B | $3.31B | $2.75B | $2.76B | $2.86B | $2.91B |
| Gross profit | $2.43B | $1.99B | — | — | — | — |
| Operating income | $1.26B | $743M | $301M | $347M | $357M | $359M |
| Net income | $943M | $569M | $693M | $270M | $241M | $238M |
| EPS (diluted) | $8.08 | $4.50 | $5.55 | $2.20 | $2.07 | — |
| Free cash flow | $1.32B | $594M | $9.9M | $542M | $509M | $558M |
| Gross margin | 63.6% | 60.1% | — | — | — | — |
| Operating margin | 32.9% | 22.4% | 10.9% | 12.6% | 12.5% | 12.3% |
| Net margin | 24.6% | 17.2% | 25.2% | 9.8% | 8.4% | 8.2% |
| Revenue growth | +1.2% | -13.5% | -16.9% | +0.2% | +3.7% | — |
| Cash + short-term investments | $603M | $454M | $1.60B | $1.16B | — | — |
| Total debt | $4.98B | $4.39B | $3.90B | $3.17B | $3.24B | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jul 5, 2026)
P/E 73.9x · P/E ex non-operating (est.) ≈53.7x · P/S 6.0x · P/FCF 31.5x · P/B 2.4x · FCF yield 3.18% · Earnings yield 1.35% · Dividend yield (paid, TTM) 0.18% · Buyback yield (TTM) 2.71%
P/E at fiscal year-ends: Dec 2025 46.8x, Dec 2024 50.7x, Dec 2023 19.7x.

## Insider sales (SEC Form 4, open-market, last ~7 months)
5 of 5 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Gonzales Anita | VP and CAO | 84 | $13K | 1.2% | Yes (adopted November 7, 2025) | Too little history (no open-market trades in 2023–2025) |
| 2026-09-21 | Krakowiak Maxwell | Please See Remarks | 1,631 | $236K | 9.9% | Yes (adopted May 19, 2026) | Too little history (no open-market trades in 2024 or 2025) |
| 2026-09-16 | Vohra Tajinder S | Please See Remarks | 7,330 | $1.0M | 52.5% | Yes (adopted May 15, 2026) | Too little history (no open-market trades in 2023) |
| 2026-07-20 | Gonzales Anita | Vice President and CAO | 85 | $9K | 1.2% | Yes (adopted November 7, 2025) | Too little history (no open-market trades in 2023–2025) |
| 2026-04-20 | Gonzales Anita | Vice President and CAO | 80 | $7K | 1.1% | Yes (adopted November 7, 2025) | Too little history (no open-market trades in 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus Hold (mean 2.78 on a 1–5 scale), 18 analysts; mean target USD 147.53 (low 110, high 175).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-13 | TD Cowen | Target raised | Buy | $130 → $175 |
| 2026-10-07 | Barclays | Target raised | Equal-Weight | $115 → $160 |
| 2026-10-06 | William Blair | Initiated | Outperform |  |
| 2026-09-04 | Keybanc | Target raised | Overweight | $125 → $165 |
| 2026-09-01 | RBC Capital | Initiated | Sector Perform | $135 |
| 2026-08-05 | Evercore ISI Group | Target raised | Outperform | $125 → $126 |
| 2026-07-06 | Evercore ISI Group | Target raised | Outperform | $110 → $125 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | +61.6% | -9.8% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +61.9% | -2.0% |
| Volatility (annualized) | 38.7% | 33.8% |
| Max drawdown | -30.1% (Jan 2026→Apr 2026) | -58.4% (Dec 2021→Sep 2025) |

## Peers (Diagnostics & Research)
MEDP (Medpace Holdings, Inc.) USD 653.96 -1.29% · CRL (Charles River Laboratories Inte) USD 339.66 -1.51% · ICLR (ICON plc) USD 185.43 +0.10% · GH (Guardant Health, Inc.) USD 162.94 -2.23% · LH (Labcorp Holdings Inc.) USD 329.93 +1.91% · DGX (Quest Diagnostics Incorporated) USD 243.28 +1.82%

## More
Full page: https://nexqual.com/RVTY · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in RVTY's own 10-K filed 2026-02-24 (https://www.sec.gov/Archives/edgar/data/31791/000003179126000012/revv-20251228.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Customer | UPS (UPS) | "We ship a significant portion of our products to our customers through independent package delivery and import/export companies, including UPS and Federal Express in the United States;" |
| Partner | Microsoft (MSFT) | "From increased collaboration to securely accessible data, the Signals NotebookTM offering accelerates research and development workflows, increases collaboration, integrates with Microsoft Office and more." |

Other companies that name RVTY in their own reports (relationship from RVTY's side):

| Relationship | Company | Their filing | Sentence |
|---|---|---|---|
| partner | Quanterix Corp (QTRX) | 10-K 2026-03-02 | "In September 2018, in connection with the acquisition of the Quantitative Pathology Solutions ("QPS") technology from PKI, Akoya entered into a license and royalty agreement with PKI, Cambridge Resear…" |

## Revenue by business segment (quarter ended 2026-07-05)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| Diagnostics | $371.0M | 50.8% | +4.7% |
| Life Sciences | $358.7M | 49.2% | -2.0% |
| Total revenue | $729.7M | 100% | — |

## Revenue by product line (quarter ended 2026-07-05)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| Product | $603.4M | 82.7% | -1.2% |
| Service | $126.3M | 17.3% | +15.2% |
| Total revenue | $729.7M | 100% | — |

## Revenue by region (quarter ended 2026-07-05)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| Americas | $325.6M | 44.6% | +0.6% |
| Europe | $229.0M | 31.4% | +12.5% |
| Asia | $175.1M | 24.0% | -9.3% |
| Total revenue | $729.7M | 100% | — |

## Company outlook (8-K filed 2026-08-04)

- "For the full year 2026, on a pro forma basis, the Company forecasts total revenue of $2.83-$2.86 billion, pro forma organic revenue growth of 4-5%, and pro forma adjusted earnings per share of $5.30-$5.40."
- "Guidance for the full year 2026 for pro forma organic revenue growth and pro forma adjusted EPS is provided on a non-GAAP basis and cannot be reconciled to the closest GAAP measures without unreasonable effort due to the unpredictability of the amounts and timing of events affecting the items the Company excludes from these non-GAAP measures."
- "Webcast Information The Company will discuss its second quarter 2026 results and its outlook for business trends during a webcast on August 4, 2026, at 7:30 a.m."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $1.30 | $1.31 | -1.1% | $694.7M | 16 |
| Next quarter (ends 2026-12-31) | $1.61 | $1.67 | -3.3% | $759.5M | 15 |
| Current fiscal year (ends 2026-12-31) | $5.35 | $5.24 | +2.0% | $2.85B | 17 |
| Next fiscal year (ends 2027-12-31) | $5.89 | $5.83 | +1.2% | $3.01B | 17 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2026-11-20 (includes earnings 2026-11-03): ±12.4%; last 8 reports averaged ±5.4%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 28 | 55.3% | ±12.4% |
| 2026-12-18 | 56 | 48.1% | ±15.0% |
| 2027-01-15 | 84 | 45.2% | ±17.3% |
| 2027-03-19 | 147 | 44.5% | ±22.3% |
| 2027-05-21 | 210 | 44.7% | ±26.8% |
| 2027-06-17 | 237 | 44.2% | ±28.2% |